AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 72-74, February 2010

Frequency of detection of methicillin-resistant Staphylococcus aureus from rectovaginal swabs in pregnant women

  • C. Buddy Creech, MD, MPH

      Affiliations

    • Department of Pediatrics, Division of Infectious Diseases, Vanderbilt University Medical Center and Vanderbilt Children's Hospital, Nashville, TN
    • Corresponding Author InformationAddress correspondence to C. Buddy Creech, MD, MPH, Pediatric Infectious Diseases and Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center and Children's Hospital, 1161 21st Avenue South, CCC-5311 MCN, Nashville, TN 37232-2573.
    • ,
  • Brandon Litzner, MS

      Affiliations

    • Vanderbilt University School of Medicine, Nashville, TN
    • ,
  • Thomas R. Talbot, MD, MPH

      Affiliations

    • Departments of Medicine and Preventive Medicine, Vanderbilt University Medical Center, Nashville, TN
    • ,
  • William Schaffner, MD

      Affiliations

    • Departments of Medicine and Preventive Medicine, Vanderbilt University Medical Center, Nashville, TN

published online 19 October 2009.

Clinical samples from 250 pregnant women undergoing screening for rectovaginal group B streptococcus colonization were evaluated concurrently for the presence of methicillin-resistant Staphylococcus aureus (MRSA). Overall, S aureus was detected in 21.6% of the women; 53.7% of the isolates were MRSA. Despite a lack of risk factors for MRSA colonization, rectovaginal MRSA was detected in 10.4% of pregnant women in this study.

Key Words: MRSA, pregnancy, Staphylococcus aureus, infection control, contact precautions

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 C.B.C. has served as a consultant to Pfizer and receives grant support from Merck, Cubist Pharmaceuticals, Astra Zeneca, and Pfizer. B.L., T.R.T, and W.S. have no potential conflicts of interest.

PII: S0196-6553(09)00756-1

doi:10.1016/j.ajic.2009.06.015

AJIC: American Journal of Infection Control
Volume 38, Issue 1 , Pages 72-74, February 2010

Article Tools